Business Context and Reporting Period
This Form 6-K filing by Sanofi-Synthelabo, dated May 4, 2004, announces the postponement of the Combined Annual General Meeting of shareholders originally scheduled for May 24, 2004. The filing is issued in the context of the company's ongoing public offer to acquire Aventis, an agreement reached on April 25, 2004.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data for the reporting period. The only specific financial metric disclosed relates to shareholder dividends:
- Interim Dividend: 0.97 euros per share, payable on May 5, 2004.
- Total Proposed Dividend: 1.02 euros per share (with the balance payable upon settlement of the Aventis offer).
Material Changes
The primary material change is the rescheduling of the Annual General Meeting. The new date must be set at least five trading days prior to the closing date of the offer for Aventis, as determined by the Autorite des Marches Financiers (AMF). The agenda for the rescheduled meeting will include votes on resolutions related to the Aventis offer and the required capital increase for share issuance.
Outlook, Risks, and Unusual Items
Management Commentary and Outlook: The Board of Directors confirmed that the postponement does not affect the proposed dividend arrangements. The company intends to distribute a supplement to the prospectus/offer to exchange regarding its revised offer for Aventis as soon as practicable.
Risks and Contingencies: The completion of the French, U.S., and German offers for Aventis is subject to the same conditions and is intended to expire simultaneously. Investors are urged to read the Registration Statement on Form F-4 and related documents for important information regarding the acquisition.
Key Facts for Investor Verification
- Verify the new date for the Annual General Meeting once announced by the Board of Directors.
- Confirm the closing date of the Sanofi-Synthelabo offer for Aventis as set by the AMF.
- Review the Registration Statement on Form F-4 (File No. 333-112314) and any supplements for details on the revised offer terms.
- Note that the total dividend of 1.02 euros remains unchanged, with the final portion contingent on the settlement of the Aventis offer.